GlassScriptPhysician profile
Howard M Futerman
NPI 1730180167
$2,314.27
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,310 · 2020: $990 · 2021: $13.78.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $775.74 | 2019-2020 | |
| Pfizer INC. | $177.36 | 2019-2020 | |
| Celgene Corporation | $177.12 | 2019 | |
| Mallinckrodt Enterprises LLC | $176.45 | 2019 | |
| Abbvie INC. | $176.40 | 2019-2020 | |
| Fidia Pharma USA INC. | $144.91 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $131.91 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $116.59 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.84 | 2019-2020 | |
| Boston Scientific Corporation | $82.62 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $59.99 | 2020 | |
| Radius Health, INC. | $59.02 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $49.50 | 2019 | |
| Abbott Laboratories | $26.13 | 2019 | |
| Lilly USA, LLC | $22.75 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $13.14 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.80 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Futerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.